M a i n r e s u l t s
Mean baseline homocysteine level was 12.2 µmol/L (1.6 mg/L). In a randomly selected subgroup of 21% of patients, the mean homocysteine level at 2 years decreased by 2.2 µmol/L (0.3 mg/L) in the intervention group and increased by 1.1 µmol/L (0.1 mg/L) in the placebo group. Groups did not differ for the primary composite endpoint, total ischemic events, or death from any cause (Table) . Hospitalization for unstable angina was increased in the intervention group (Table) .
C o n c l u s i o n
In patients with vascular disease, lowering plasma homocysteine levels with folic acid and B vitamins did not reduce risk for the composite endpoint of myocardial infarction, stroke, or death from cardiovascular causes more than placebo. 
C o m m e n t a r y
It's déjà vu all over again. On the basis of a plausible biological rationale, observational studies consistently showing an association between a risk factor and subsequent CVD, and small experimental studies showing an effect of the intervention on surrogate endpoints, it is proposed that a cheap and simple pill can have a dramatic effect on CV outcomes. In this case, the cheap and simple pill is a combination of folic acid and B vitamins. The hypothesis is that taking this pill will reduce plasma levels of homocysteine (which a large body of epidemiologic evidence shows is associated with CV risk) and that this effect will, in turn, reduce CV events.
This compelling rationale has now been tested in 3 related randomized controlled trials. The first trial compared a high-dose combination of folate and B vitamins with a control pill of low doses of the same vitamins in 3680 patients who had recently had a nondisabling stroke and had fasting total homocysteine levels > 25th percentile for stroke patients (1) . Despite documented increases in blood levels of folate and vitamin B 12 , the intervention had no effect on stroke, a composite endpoint of coronary events, or death over a 2-year period.
These disappointing results were reinforced by the findings of the HOPE-2 and NORVIT trials. In HOPE-2, men and women ≥ 55 years of age with CVD, 55% and 40% of whom had hypertension and diabetes, respectively, were randomized to a combination of folate and vitamins B 6 and B 12 or placebo. Despite an average 22% reduction in plasma homocysteine levels, there was no effect of the intervention on the composite endpoint of CVD death, MI, or stroke. In analyses of each outcome separately, a beneficial effect of the intervention on stroke was observed, but this is unlikely to be a causal association, since such an effect was not observed in either of the other 2 trials. Like the authors of HOPE-2, I believe this finding was an overestimate of the effect or due to chance.
In NORVIT, 3749 patients with recent MI were randomized to placebo, folate and vitamin B 12 , vitamin B 6 , or the combination of folate and vitamins B 12 and B 6 . These treatments predictably lowered plasma homocysteine levels by an average of 27%. However, after more (continued on page 3)
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Q u e s t i o n
In patients with acute myocardial infarction (MI), does lowering plasma homocysteine levels with folic acid plus vitamin B 12 or vitamin B 6 reduce risk for major vascular events? Patients: 3749 patients 30 to 85 years of age (mean age 63 y, 74% men) with acute MI in the previous 7 days. Exclusion criteria included life expectancy < 4 years. Intervention: A combined capsule with 0.8 mg folic acid, 40 mg vitamin B 6 , and 0.4 mg vitamin B 12 (n = 937); 0.8 mg folic acid and 0.4 mg vitamin B 12 (n = 935); 40 mg vitamin B 6 (n = 934); or placebo (n = 943), taken once daily. The 2 folic acid groups received a loading dose of 5 mg folic acid daily for 2 weeks. Outcomes: A composite endpoint of MI, stroke, or sudden death from coronary heart disease. Secondary outcomes included MI, stroke, hospitalization for unstable angina, coronary revascularization, and death from any cause.
M e t h o d s
Patient follow-up: 99% (intention-to-treat analysis).
M a i n r e s u l t s
Mean baseline homocysteine levels were 12.9 to 13.3 µmol/L (1.7 to 1.8 mg/L). Mean homocysteine level at 2 years decreased by 3.4 to 3.7 µmol/L (0.5 mg/L) in the 2 folic acid groups and increased by 0.4 to 0.5 µmol/L (0.1 mg/L) in the 2 groups without folic acid. Groups did not differ for any clinical outcome (Table) .
C o n c l u s i o n s
In patients with myocardial infarction, lowering plasma homocysteine levels with folic acid and vitamin B 12 , with or without vitamin B 6 , did not reduce risk for the composite endpoint of myocardial infarction, stroke, or death from coronary heart disease. 
